Peptide analogs for treating diseases and disorders
Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.
1. A peptide selected from the group consisting of:
SEQ ID NO: 15
AcCSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2,
SEQ ID NO: 12
AcCSNLSTCVLGRLSQELHRLQTFPRTDVGANTAcY,
and
SEQ ID NO: 17
SuccCSNLSTCVLGKLSQELHKLQTYPRTDVGANAY-NH2.
2. The peptide as claimed in claim 1 , wherein the peptide is formulated for enteral administration.
3. The peptide as claimed in claim 1 , wherein the peptide is formulated for parenteral administration.
4. The peptide as claimed in claim 1 , wherein the peptide is formulated with a carrier for oral administration.
5. The peptide as claimed in claim 4 , wherein the carrier comprises N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), sodium salt of 10-(2-Hydroxybenzamido)decanoic acid (SNAD), or sodium salt of N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC).
6. A pharmaceutical composition for oral administration comprising the peptide of claim 1 formulated in coated citric acid particles.